Novartis Pays $150M to Nab a Phase 3-Ready Protein Degrader for Prostate Cancer
Novartis gains global rights to an Arvinas protein degrading drug that targets the androgen receptor to treat prostate cancer. The deal also includes a preclinical molecule addressing an androgen receptor variant.